Latest News - Bristol-Myers Squibb
Top Corporates Hub
Bristol-Myers Squibb
Bristol-Myers Squibb Company Confirms Efficacy and Safety of Sotyktu for Psoriatic Arthritis and Lupus with New Long-Term Data
31.10.2025 09:42
Bristol-Myers Squibb Company (NYSE:BMY) is one of the best NYSE stocks to buy and hold for the next decade. On October 27, Bristol Myers Squibb announced new Week 52 data from its pivotal Phase 3 POETYK PsA-1 trial. These results further confirmed the efficacy and safety of Sotyktu (deucravacitinib) for treating adults with active psoriatic […]
Atrial Fibrillation Eight-Market Drug Forecast and Market Analysis 2022-2024 & 2025-2032: Market to Remain Dominated by Bayer and Bristol Myers Squibb; Growth Driven by Milvexian Launch
31.10.2025 09:26
The AF market offers opportunities driven by new pipeline drugs such as FXI/FXIa inhibitors addressing bleeding concerns and growing prevalence of treated AF cases. However, growth is challenged by generic erosion of NOACs and competition from cost-effective generics, hindering new entry uptake.Dublin, Oct. 31, 2025 (GLOBE NEWSWIRE) -- The "Atrial Fibrillation: Eight-Market Drug Forecast and Market Analysis - Update" report has been added to ResearchAndMarkets.com's offering.The table below pres
Strong Trial Results in Autoimmune Diseases Might Change the Case for Investing in Bristol-Myers Squibb (BMY)
31.10.2025 03:22
In October 2025, Bristol-Myers Squibb reported positive Phase 3 and Phase 2 trial results for Sotyktu in psoriatic arthritis and systemic lupus erythematosus, and early promising data on its next-generation CD19-targeted CAR T cell therapy across multiple autoimmune diseases at prominent medical conferences. These clinical trial updates highlight Bristol-Myers Squibb's progress in expanding its immunology portfolio, strengthening its pipeline for potential future regulatory approvals and...
Bristol-Myers Squibb (BMY) Stock Trades Up, Here Is Why
30.10.2025 19:36
Shares of biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) jumped 4.3% in the morning session after the company posted third-quarter financial results that beat expectations and raised its full-year sales forecast. Total revenues for the quarter came in at $12.22 billion, an increase of 2.8% from the same period a year ago, surpassing analyst estimates. The company also reported adjusted earnings of $1.63 per share, which was better than anticipated. Following these results, Bristol-Mye
Bladder Cancer Market - Global and Regional Analysis and Forecast (2025-2035) Featuring Merck & Co., Bristol Myers Squibb, Astellas Pharma, AstraZeneca, and Johnson & Johnson
30.10.2025 17:16
Dublin, Oct. 30, 2025 (GLOBE NEWSWIRE) -- The "Bladder Cancer Market - A Global and Regional Analysis: Analysis and Forecast, 2025-2035" has been added to ResearchAndMarkets.com's offering.The market's growth is primarily driven by the rising incidence of bladder cancer, advancements in diagnostic technologies, and the growing availability of innovative treatments such as immunotherapy and targeted therapies for bladder cancer management.Market Lifecycle StageThe market is currently in the expan
Bristol-Myers Squibb Company (BMY) Q3 2025 Earnings Call Transcript
30.10.2025 16:06
Bristol-Myers Squibb Company (BMY) Q3 2025 Earnings Call October 30, 2025 8:00 AM EDTCompany ParticipantsChuck TrianoChristopher Boerner - CEO &...
Estée Lauder's turnaround plan, Mastercard beats Q3 estimates
30.10.2025 14:40
Market Catalysts host Julie Hyman tracks several of the day's top trending stock tickers, including Estée Lauder (EL) beating profit estimates amid its brand turnaround plan, Mastercard (MA) topping third quarter expectations on its top and bottom lines, and Bristol-Myers Squibb (BMY) raising its revenue outlook. To watch more expert insights and analysis on the latest market action, check out more Market Catalysts.
BMY Beats on Q3 Earnings and Sales, Raises 2025 Sales View
30.10.2025 14:32
Bristol-Myers' strong Q3 results, powered by Opdivo, Reblozyl and Breyanzi, led to a revenue guidance boost despite legacy drug declines.
Bristol Myers (BMY) Reports Q3 Earnings: What Key Metrics Have to Say
30.10.2025 13:30
The headline numbers for Bristol Myers (BMY) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Bristol-Myers Squibb Q3 Earnings Review: Despite Today's Gains, I See Trouble Ahead
30.10.2025 13:22
Bristol-Myers Squibb (NYSE:BMY) Reports Bullish Q3
30.10.2025 13:21
Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) reported revenue ahead of Wall Streets expectations in Q3 CY2025, with sales up 2.8% year on year to $12.22 billion. The company’s full-year revenue guidance of $47.75 billion at the midpoint came in 0.9% above analysts’ estimates. Its non-GAAP profit of $1.63 per share was 7.6% above analysts’ consensus estimates.
United States Vitiligo Market Research Report 2025-2033 by Diseases Type, Treatment Type, End User, Regions and Company Analysis
30.10.2025 12:58
The United States vitiligo market is projected to grow from $202.87 million in 2024 to $320.71 million by 2033, driven by a 5.22% CAGR from 2025. This growth is fueled by increasing awareness, innovative therapies, and improved diagnostic methods. Key treatment advancements include biologics, phototherapy, and topical solutions. Challenges include limited curative options and high treatment costs. States like California, New York, Texas, and Florida lead due to strong healthcare infrastructure.
Are Wall Street Analysts Predicting Bristol-Myers Squibb Stock Will Climb or Sink?
30.10.2025 12:27
Bristol-Myers Squibb has significantly underperformed the broader market over the past year, and analysts are cautious about the stock’s prospects.
Bristol Myers Squibb (BMY) Q3 Earnings and Revenues Surpass Estimates
30.10.2025 12:10
Bristol Myers (BMY) delivered earnings and revenue surprises of +10.14% and +3.33%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Bristol-Myers Squibb ups annual outlook as Q3 print exceeds estimates
30.10.2025 11:38
Investing.com -- Bristol-Myers Squibb lifted its full-year outlook slightly after reporting third-quarter earnings and revenue that beat market expectations.
Bristol Myers Squibb Profit Soars, Raises Revenue Guidance
30.10.2025 11:11
Bristol Myers Squibb added nearly $1 billion to its bottom line in the third quarter as costs came down and revenue climbed on the strength of its newer drugs.
Bristol Myers: Q3 Earnings Snapshot
30.10.2025 11:10
PRINCETON, N.J. (AP) — Bristol Myers Squibb Co. (BMY) on Thursday reported third-quarter earnings of $2.2 billion. On a per-share basis, the Princeton, New Jersey-based company said it had profit of $1.08. Earnings, adjusted for non-recurring costs, came to $1.63 per share.
Bristol Myers Squibb Reports Third Quarter Financial Results for 2025
30.10.2025 10:59
PRINCETON, N.J., October 30, 2025--Bristol Myers Squibb Reports Third Quarter Financial Results for 2025
Bristol-Myers Squibb Company 2025 Q3 - Results - Earnings Call Presentation
30.10.2025 08:30
2025-10-30. The following slide deck was published by Bristol-Myers Squibb Company in conjunction with their 2025 Q3 earnings call.
Global Initiative To Demonstrate Operational Excellence in Nigeria for Metastatic Colorectal Cancer Patients
29.10.2025 11:00
NORTHAMPTON, MA / ACCESS Newswire / October 29, 2025 / Bristol-Myers Squibb Company - Recently, the Innovative Cancer Medicines (ICM) initiative announced the enrollment of the first Nigerian patient in a pioneering demonstration project to provide ...